Genovese, Mark C <br/><br/>
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.  [electronic resource] 

 -  Arthritis and rheumatism  Feb 2011 
 - 337-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1529-0131 
<br/><br/><label>Standard No.: </label>10.1002/art.30114  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aminopyridines<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Resistance<br/>Enzyme Inhibitors--therapeutic use<br/>Female<br/>Health Status<br/>Humans<br/>Immunologic Factors--pharmacology<br/>Intracellular Signaling Peptides and Proteins--antagonists & inhibitors<br/>Joints--drug effects<br/>Male<br/>Middle Aged<br/>Morpholines<br/>Oxazines--therapeutic use<br/>Prodrugs--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyridines--therapeutic use<br/>Pyrimidines<br/>Severity of Illness Index<br/>Syk Kinase<br/>Treatment Outcome<br/>Young Adult